Enterprise Associates 16 New Purchases 554,250 Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock

Marker Therapeutics, Inc. (NASDAQ:MRKR) major shareholder Enterprise Associates 16 New purchased 554,250 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $1,773,600.00. Following the completion of the purchase, the insider now directly owns 1,625,678 shares of the company’s stock, valued at approximately $5,202,169.60. This represents a 51.73 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Marker Therapeutics Trading Down 1.2 %

MRKR opened at $3.38 on Wednesday. Marker Therapeutics, Inc. has a 12 month low of $2.44 and a 12 month high of $6.16. The business’s 50-day moving average price is $3.72 and its 200-day moving average price is $3.84.

Hedge Funds Weigh In On Marker Therapeutics

An institutional investor recently bought a new position in Marker Therapeutics stock. Invst LLC bought a new position in Marker Therapeutics, Inc. (NASDAQ:MRKR) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned 0.22% of Marker Therapeutics as of its most recent SEC filing. 22.39% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH increased their target price on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a report on Monday, October 21st.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.